Browse drugs

…in over one-third of patients, especially in DLBCL treated with axicabtagene ciloleucel, while none were reported with tisagenlecleucel. Despite low mo…

…st BCMA-negative HMC3 cells. In contrast, our novel CAR T-cell, LTG3551, exhibited low tonic signaling, compelling anti-tumor activity,…